These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27694758)

  • 1. Study of hTERT and Histone 3 Mutations in Medulloblastoma.
    Viana-Pereira M; Almeida GC; Stavale JN; Malheiro S; Clara C; Lobo P; Pimentel J; Reis RM
    Pathobiology; 2017; 84(2):108-113. PubMed ID: 27694758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
    Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM
    Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors.
    Fan X; Wang Y; Kratz J; Brat DJ; Robitaille Y; Moghrabi A; Perlman EJ; Dang CV; Burger PC; Eberhart CG
    Am J Pathol; 2003 Jun; 162(6):1763-9. PubMed ID: 12759234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.
    Remke M; Ramaswamy V; Peacock J; Shih DJ; Koelsche C; Northcott PA; Hill N; Cavalli FM; Kool M; Wang X; Mack SC; Barszczyk M; Morrissy AS; Wu X; Agnihotri S; Luu B; Jones DT; Garzia L; Dubuc AM; Zhukova N; Vanner R; Kros JM; French PJ; Van Meir EG; Vibhakar R; Zitterbart K; Chan JA; Bognár L; Klekner A; Lach B; Jung S; Saad AG; Liau LM; Albrecht S; Zollo M; Cooper MK; Thompson RC; Delattre OO; Bourdeaut F; Doz FF; Garami M; Hauser P; Carlotti CG; Van Meter TE; Massimi L; Fults D; Pomeroy SL; Kumabe T; Ra YS; Leonard JR; Elbabaa SK; Mora J; Rubin JB; Cho YJ; McLendon RE; Bigner DD; Eberhart CG; Fouladi M; Wechsler-Reya RJ; Faria CC; Croul SE; Huang A; Bouffet E; Hawkins CE; Dirks PB; Weiss WA; Schüller U; Pollack IF; Rutkowski S; Meyronet D; Jouvet A; Fèvre-Montange M; Jabado N; Perek-Polnik M; Grajkowska WA; Kim SK; Rutka JT; Malkin D; Tabori U; Pfister SM; Korshunov A; von Deimling A; Taylor MD
    Acta Neuropathol; 2013 Dec; 126(6):917-29. PubMed ID: 24174164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of KBTBD4 Mutations in Molecularly Classified Brazilian Medulloblastomas.
    Leal LF; Cavagna RO; Campanella NC; Mançano B; Almeida GC; Matsushita M; Almeida Junior CR; Saggioro F; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; Neder L; Reis RM
    J Neuropathol Exp Neurol; 2019 Sep; 78(9):788-790. PubMed ID: 31403685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and mutational profiles of adult medulloblastoma groups.
    Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase promoter mutations and copy number alterations in solitary fibrous tumours.
    Lin Y; Seger N; Tsagkozis P; Hesla AC; Ghaderi M; Chen Y; Ehnman M; Warsito D; Wejde J; Larsson O; Haglund F
    J Clin Pathol; 2018 Sep; 71(9):832-839. PubMed ID: 29703757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.
    Braunstein I; Cohen-Barak O; Shachaf C; Ravel Y; Yalon-Hacohen M; Mills GB; Tzukerman M; Skorecki KL
    Cancer Res; 2001 Jul; 61(14):5529-36. PubMed ID: 11454703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of N-ras gene mutations in medulloblastomas by polymerase chain reaction and oligonucleotide probes in formalin-fixed, paraffin-embedded tissues.
    Iolascon A; Lania A; Badiali M; Pession A; Saglio G; Giangaspero F; Miraglia del Giudice E; Perrotta S; Cutillo S
    Med Pediatr Oncol; 1991; 19(4):240-5. PubMed ID: 2056968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebellar high-grade gliomas do not present the same molecular alterations as supratentorial high-grade gliomas and may show histone H3 gene mutations.
    Tauziède-Espariat A; Saffroy R; Pagès M; Pallud J; Legrand L; Besnard A; Lacombe J; Lot G; Borha A; Tazi S; Adle-Biassette H; Polivka M; Lechapt E; Varlet P
    Clin Neuropathol; 2018; 37(5):209-216. PubMed ID: 29809131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis.
    Hui AB; Takano H; Lo KW; Kuo WL; Lam CN; Tong CY; Chang Q; Gray JW; Ng HK
    Clin Cancer Res; 2005 Jul; 11(13):4707-16. PubMed ID: 16000565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
    Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
    J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
    Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D
    Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
    Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
    J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters.
    Atkinson SP; Hoare SF; Glasspool RM; Keith WN
    Cancer Res; 2005 Sep; 65(17):7585-90. PubMed ID: 16140922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HTERT promoter methylation and single nucleotide polymorphism (-245 T>C) affect renal cell carcinoma behavior in Serbian population.
    Trifunovic J; Basta Jovanovic G; Nikolic N; Carkic J; Marjanovic A; Brankovic M; Radojevic Skodric S; Prvanovic M; Jovanovic A; Dzamic Z; Milasin J
    J BUON; 2018; 23(6):1887-1892. PubMed ID: 30610818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of PinX1 in medulloblastomas.
    Chang Q; Pang JC; Li J; Hu L; Kong X; Ng HK
    Int J Cancer; 2004 Mar; 109(2):309-14. PubMed ID: 14750185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours.
    Lindsey JC; Schwalbe EC; Potluri S; Bailey S; Williamson D; Clifford SC
    Acta Neuropathol; 2014 Feb; 127(2):307-9. PubMed ID: 24337442
    [No Abstract]   [Full Text] [Related]  

  • 20. MiR-495 is a Predictive Biomarker that Downregulates GFI1 Expression in Medulloblastoma.
    Wang C; Yun Z; Zhao T; Liu X; Ma X
    Cell Physiol Biochem; 2015; 36(4):1430-9. PubMed ID: 26160036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.